X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74) 74
index medicus (72) 72
animals (59) 59
immunology (54) 54
anti-cd25 monoclonal-antibody (40) 40
transplantation (39) 39
female (38) 38
mice (37) 37
t-lymphocytes, regulatory - immunology (37) 37
t cells (34) 34
male (32) 32
interleukin-2 receptor alpha subunit - immunology (30) 30
antibodies, monoclonal - therapeutic use (28) 28
anti-cd25 (26) 26
immunosuppressive agents - therapeutic use (26) 26
regulatory t-cells (24) 24
adult (22) 22
middle aged (21) 21
anti-cd25 monoclonal antibody (20) 20
surgery (20) 20
immunotherapy (19) 19
oncology (19) 19
regulatory t cells (19) 19
basiliximab (18) 18
daclizumab (18) 18
t-lymphocytes - immunology (18) 18
t-lymphocytes, regulatory - metabolism (18) 18
chemical and pharmacologic phenomena (17) 17
flow cytometry (17) 17
mice, inbred c57bl (16) 16
cutting edge (15) 15
cytokines (15) 15
foxp3 (15) 15
hematology (15) 15
hemic and immune systems (15) 15
immunoglobulin g - therapeutic use (15) 15
monoclonal-antibody (15) 15
anti-cd25 antibody (14) 14
cancer (14) 14
depletion (14) 14
immunosuppression (14) 14
interleukin-2 receptor alpha subunit - metabolism (14) 14
analysis (13) 13
antibodies, monoclonal, humanized (13) 13
cd25 (13) 13
health aspects (13) 13
lymphocytes (13) 13
lymphocytes t (13) 13
receptors, interleukin-2 - immunology (13) 13
treatment outcome (13) 13
antibodies, monoclonal - immunology (12) 12
article (12) 12
interleukin-2 (12) 12
kidney transplantation (12) 12
monoclonal antibodies (12) 12
autoimmunity (11) 11
dendritic cells (11) 11
expression (11) 11
induction (11) 11
lymphocyte depletion (11) 11
regulatory t cell (11) 11
antibodies (10) 10
immune-responses (10) 10
mice, inbred balb c (10) 10
rejection (10) 10
versus-host-disease (10) 10
acute rejection (9) 9
anti-cd25 treatment (9) 9
antibodies, monoclonal - administration & dosage (9) 9
cd25 antigen (9) 9
cell biology (9) 9
forkhead transcription factors - metabolism (9) 9
graft vs host disease - prevention & control (9) 9
immune system (9) 9
immunosuppressive agents - administration & dosage (9) 9
in-vivo (9) 9
kidney transplantation - immunology (9) 9
prevention (9) 9
receptor (9) 9
retrospective studies (9) 9
t-lymphocytes, regulatory - drug effects (9) 9
trial (9) 9
vaccines (9) 9
bone-marrow-transplantation (8) 8
care and treatment (8) 8
cd4-positive t-lymphocytes - immunology (8) 8
child (8) 8
cyclosporine (8) 8
forkhead transcription factors - immunology (8) 8
graft rejection - prevention & control (8) 8
il-2 (8) 8
immunological self-tolerance (8) 8
immunoregulation (8) 8
infection (8) 8
interleukin-2 receptor alpha subunit - antagonists & inhibitors (8) 8
lymphocyte depletion - methods (8) 8
multiple sclerosis (8) 8
mycophenolate-mofetil (8) 8
receptors, interleukin-2 - antagonists & inhibitors (8) 8
recipients (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF EXPERIMENTAL MEDICINE, ISSN 0022-1007, 04/2018, Volume 215, Issue 4, pp. 1169 - 1186
The pathophysiology of drug-resistant pediatric epilepsy is unknown. Flow cytometric analysis of inflammatory leukocytes in resected brain tissues from 29... 
INTERLEUKIN 17 | MEDICINE, RESEARCH & EXPERIMENTAL | REMITTING MULTIPLE-SCLEROSIS | DRUG-RESISTANT EPILEPSY | TEMPORAL-LOBE EPILEPSY | BRAIN INFLAMMATION | MICROGLIA | DESCRIPTIVE EPIDEMIOLOGY | ANTI-CD25 MONOCLONAL-ANTIBODY | IMMUNOLOGY | EXPRESSION | SEIZURE SEVERITY
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2010, Volume 9, Issue 4, pp. 381 - 390
Summary Background Daclizumab, a humanised monoclonal antibody, reduced multiple sclerosis disease activity in previous non-randomised studies. We aimed to... 
Neurology | NATURAL-KILLER-CELLS | IN-VITRO | ANTI-CD25 ANTIBODY DACLIZUMAB | CD56(BRIGHT) | BLOCKADE | T-CELLS | CLINICAL NEUROLOGY | T-Lymphocytes - physiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Magnetic Resonance Imaging - methods | Antibodies, Monoclonal - therapeutic use | Male | Interferon-beta - therapeutic use | Young Adult | Antibodies, Monoclonal, Humanized | Lymphocytes - physiology | Interferon-beta - adverse effects | T-Lymphocytes - drug effects | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Immunosuppressive Agents - administration & dosage | Interferon-beta - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - pathology | CD56 Antigen - metabolism | Multiple Sclerosis, Chronic Progressive - physiopathology | Double-Blind Method | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Multiple Sclerosis, Chronic Progressive - pathology | Treatment Outcome | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Brain - drug effects | Antibodies, Monoclonal - administration & dosage | Lymphocytes - drug effects | Adolescent | Brain - pathology | Immunosuppressive Agents - adverse effects | Cell Proliferation - drug effects | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Clinical trials | Multiple sclerosis | Biological response modifiers | Consulting services | Interferon beta
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 4, pp. 1128 - 1135
Purpose Immunotherapy could be a useful adjunct to standard cytotoxic therapies such as radiation in patients with micrometastatic disease, although successful... 
Radiology | Hematology, Oncology and Palliative Medicine | Anti-CD25 therapy | Radiation therapy | T regulatory cells | Transgenic adenocarcinoma of mouse prostate | TUMOR | ADENOSINE | PERIPHERAL-BLOOD | RESPONSES | CANCER-PATIENTS | THERAPY | ONCOLOGY | TRANSCRIPTION FACTOR FOXP3 | PROSTATE-CANCER | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ANTIGEN | Whole-Body Irradiation | Prostatic Neoplasms - radiotherapy | CD4-Positive T-Lymphocytes - radiation effects | Male | Prostatic Neoplasms - immunology | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - radiation effects | Immunotherapy | Female | Scattering, Radiation | Adenocarcinoma - radiotherapy | Radiation Tolerance - immunology | Adenocarcinoma - immunology | Mice, Inbred C57BL | Biomarkers - analysis | Hindlimb - radiation effects | Mice, Transgenic | Spleen - cytology | Lymph Nodes - cytology | Animals | CD24 Antigen - analysis | Forkhead Transcription Factors - analysis | Cell Line, Tumor | Interleukin-2 Receptor alpha Subunit - analysis | Lymphocyte Count | Mice | Dose-Response Relationship, Radiation | T cells | Radiotherapy | Radiation | PROSTATE | IRRADIATION | PATIENTS | IMMUNOTHERAPY | LEGS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | LYMPHOCYTES | anti-CD25 therapy | transgenic adenocarcinoma of the mouse prostate | radiation therapy
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2012, Volume 18, Issue 3, pp. 466 - 472
Patients suffering from high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) secondary to MDS (sAML) are characterized by poor response... 
Graft-versus-host disease | Interleukin-2 receptor antagonists | Anti-CD25 monoclonal antibody | Unrelated donor | Peripheral blood stem cell transplantation
Journal Article
Cell Reports, ISSN 2211-1247, 10/2018, Volume 25, Issue 5, pp. 1204 - 1213.e4
Although Foxp3 regulatory T cells (Tregs) require interleukin-2 (IL-2) for their development, it has been unclear whether continuing IL-2 signals are needed to... 
IL-15 | IL-2 | CD25 | regulatory T cell | IL-7 | regulatory T cell | INTERLEUKIN-2 | FOXP3 EXPRESSION | ACTIVATION | ALPHA-CHAIN | IN-VIVO | REGULATORY T-CELLS | ANTI-CD25 MONOCLONAL-ANTIBODY | RECEPTOR | MICE | CUTTING EDGE | CELL BIOLOGY
Journal Article
Microbes and Infection, ISSN 1286-4579, 12/2017, Volume 19, Issue 12, pp. 626 - 634
Elderly humans over 65 years old are at great risk to pathogenesis by influenza virus infection. However, although influenza vaccines provide effective... 
Aging | Vaccine | Influenza | Regulatory T cell | INFECTIOUS DISEASES | HUMAN INFECTION | EFFICACY | INSECT CELLS | VACCINATION | MICROBIOLOGY | IMMUNOLOGY | IMMUNOSENESCENCE | LIVE | A VIRUS | EVOLUTION | ANTI-CD25 MONOCLONAL-ANTIBODY | VACCINES | vaccine | aging | regulatory T cell
Journal Article